Alpha Tau Medical Ltd (DRTS) Return on Equity ROE from the fourth quarter 2025 to fourth quarter 2023 and annually, average high and low, overall ranking from Dec 31 2025 to Dec 31 2023 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Alpha Tau Medical Ltd  (NASDAQ: DRTS)

Alpha Tau Medical Ltd's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Alpha Tau Medical Ltd in the fourth quarter 2025?
Alpha Tau Medical Ltd achieved a return on average equity (ROE) of 53.63 % in its fourth quarter 2025, this is above DRTS's average return on equity of 17.77%.
Alpha Tau Medical Ltd shareholder's equity over the 12 months ending in its fourth quarter 2025 are valued at $79 million

ROE has advanced compared to 38.43% in the third quarter 2025, due to net income growth.

Within the Medical Equipment & Supplies industry 6 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the third quarter 2025 from to 147.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2023)
IV. Quarter
Y / Y Equity Change 23.03 % 4.16 % 2.54 % -8.73 % -
Y / Y Net Income Change 46.2 % - - - -13.64 %
Net Income (TTM) in Millions 43 29 29 29 29
Return On Equity (TTM) 53.63 % 38.43 % 38.82 % 39.1 % 38.16 %
DRTS's Total Ranking # 147 # # # #
Equity (TTM) in Millions 77 77 87 77 63
Seq. Equity Change 0 % -10.99 % 12.35 % 23.03 % -15.34 %
Seq. Net Income Change - - - - -

Back to DRTS Management Effectiveness >> DRTS's 5 Years Annual ROE >> Compare DRTS ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 7
Sector # 36
Overall # 147

Return On Equity Statistics
High Average Low
55.29 %
17.77 %
-50.67 %
(Dec 31 2025)   (Dec 31 2024)





DRTS Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 77 63 84 106 -35
Y / Y Equity Change 23.03 % -25.82 % -20.05 % - -
Net Income in Millions 43 -32 29 34 27
Y / Y Net Income Change - - -13.64 % 23.8 % -
Return On Equity 55.29 % -50.67 % 34.52 % 31.95 % -

Back to DRTS Management Effectiveness >> DRTS's 5 Years Annual ROE >> Compare DRTS ROE to its Competitors




Annual Roe Comment
In 2025 ROE improved to 55.29 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Medical Equipment & Supplies Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
DRTS's' Return on Equity at Yahoo Finance
DRTS's Roe Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for DRTS's Competitors
Subscribers only: Roe for Alpha Tau Medical Ltd's Suppliers
Subscribers only: Return On Equity for DRTS's Customers




Companies with similar Return On Equity at Dec 31 2025, within Healthcare Sector ROE
Advanced Biomed Inc.  142.91 %
Check Cap Ltd  120.45 %
Medpace Holdings Inc   118.82 %
Tg Therapeutics Inc   101.12 %
Eli Lilly And Company  97.61 %
Amgen Inc   96.65 %
Halozyme Therapeutics Inc   92.67 %
Earth Science Tech Inc   82.09 %
Exelixis Inc   81.25 %
Elite Pharmaceuticals Inc   80.28 %
Zevra Therapeutics Inc   74.63 %
3m Company  71.32 %
Entera Bio Ltd   70.43 %
Aurinia Pharmaceuticals Inc   70.37 %
Idexx Laboratories Inc  69.78 %
Alnylam Pharmaceuticals Inc   69.25 %
Enlivex Therapeutics Ltd  63.85 %
Dariohealth Corp   59.48 %
Nrc Health  58.51 %
Zoetis Inc   56.31 %
Alpha Tau Medical Ltd  55.29 %
Transmedics Group Inc   53.88 %
Pulmatrix Inc   53.50 %
Abeona Therapeutics Inc   53.18 %
Novo Nordisk A  52.79 %
Medinotec Inc   52.76 %
Concentra Group Holdings Parent Inc   47.62 %
Theravance Biopharma inc   46.03 %
Galmed Pharmaceuticals Ltd   43.72 %
Acadia Pharmaceuticals Inc   41.90 %

Date modified: 2026-07-07T10:26:37+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.